Dividend comparison
NOBL vs CGDV: Which Is Better for Income?
Fees, yield, total returns, drawdowns, holdings overlap and dividend history for ProShares - S&P 500 Dividend Aristocrats ETF and Capital Group Dividend Value ETF, side by side. Updated October 21, 2026.
- Fees. CGDV is cheaper at 0.33% a year versus 0.35% for NOBL. On $10,000 that is $2 a year less in fees.
- Income. NOBL pays more income, yielding 2.04% over the last twelve months versus 1.23% for CGDV. That is about $82 more a year on $10,000. Both pay quarterly.
- Performance. Over the last 3 years, CGDV returned 94.7% versus 42.6% for NOBL, with dividends reinvested. $10,000 would have grown to $19,473 in CGDV and $14,258 in NOBL.
- Risk. CGDV has been the bumpier ride. Its worst peak-to-trough decline over the last 3 years was -21.9%, against -17.9% for NOBL.
- Diversification. NOBL holds 71 positions and CGDV holds 58.
- Dividend growth. CGDV grew its yearly payout 7.0% a year over the last 2 years, versus 4.6% for NOBL.
- Size. CGDV is the larger fund with $38.8 billion in assets, against $11.4 billion for NOBL.
Bottom line: NOBL fits better if you care most about more income today and smaller drawdowns. CGDV fits better if you care most about stronger 3-year returns and faster dividend growth.
| Metric | NOBL ProShares - S&P 500 Dividend Aristocrats ETF | CGDV Capital Group Dividend Value ETF |
|---|---|---|
| Dividend yield (TTM) | 2.04% | 1.23% |
| Dividend / share (TTM) | $1.17 | $0.60 |
| Payout frequency | Quarterly | Quarterly |
| Last dividend | $0.2825 on Sep 29, 2026 | $0.1522 on Oct 1, 2026 |
| Ex-dividend date | Sep 23, 2026 | Sep 30, 2026 |
| Dividend growth (CAGR) | 4.6% over 4 yrs | 7.0% over 2 yrs |
| Price | $57.49 | $49.17 |
| Dividend growth streak | 3 years | 2 years |
| Beta | 0.62 | 0.90 |
| Max drawdown (5Y) | -17.9% | -21.9% |
| Market cap | $11.51B | $38.84B |
| Exchange | CBOE | AMEX |
| Expense ratio | 0.35% | 0.33% |
| Assets under management | $11.44B | $38.84B |
| Number of holdings | 71 | 58 |
| Top 10 concentration | 16.8% | — |
NOBL
$17.00/mo
$204 /yr at 2.04% yield
CGDV
$10.21/mo
$123 /yr at 1.23% yield
| Year | NOBL | CGDV |
|---|---|---|
| 2025 | $1.1127 | $0.5649 |
| 2024 | $1.0226 | $0.5636 |
| 2023 | $0.9969 | $0.4932 |
| 2022 | $0.8720 | — |
| 2021 | $0.9301 | — |
Expect stretches of underperformance versus the broad market whenever leadership comes from the high-growth, low-yield companies these screens exclude.
| Period | NOBL | CGDV |
|---|---|---|
| 1 month | 3.81% | 0.43% |
| 3 months | 2.19% | 0.78% |
| Year to date | 12.20% | 12.67% |
| 1 year | 14.09% | 16.68% |
| 3 years | 42.58% | 94.73% |
| 5 years | 36.72% | — |
- NOBL
- CGDV
Both series indexed to 100 on 2022-02-24 using the adjusted closing price series. Past performance does not guarantee future results.
- NOBL
- CGDV
NOBL71 holdings total
| Name | Weight |
|---|---|
| BDXBECTON DICKINSON AND CO | 1.79% |
| FDSFACTSET RESEARCH SYSTEMS INC | 1.77% |
| ADPAUTOMATIC DATA PROCESSING | 1.69% |
| CVXCHEVRON CORP | 1.67% |
| XOMEXXONMOBIL HOLDINGS CORP | 1.66% |
| EMREMERSON ELECTRIC CO | 1.65% |
| ERIEERIE INDEMNITY COMPANY-CL A | 1.65% |
| IBMINTL BUSINESS MACHINES CORP | 1.65% |
| CAHCARDINAL HEALTH INC | 1.64% |
| ROPROPER TECHNOLOGIES INC | 1.63% |
Quick verdict
NOBL fits better if you care most about more income today and smaller drawdowns. CGDV fits better if you care most about stronger 3-year returns and faster dividend growth. Model the holding inside your real portfolio before deciding.
Frequently asked questions
Is NOBL or CGDV better for dividend income?
What is the difference between NOBL and CGDV?
Which is cheaper, NOBL or CGDV?
Which has performed better, NOBL or CGDV?
Which is riskier, NOBL or CGDV?
How often do NOBL and CGDV pay dividends?
How much income does $10,000 in NOBL vs CGDV generate?
Can I hold both NOBL and CGDV?
Where can I compare NOBL vs CGDV with my full portfolio?
Related comparisons
For informational and educational purposes only. Not investment advice. Past performance and current yields do not guarantee future results. Verify figures independently before making investment decisions.